VIVUS (VVUS) Peers Pressured as Analyst Takes Cautious Stance on Obesity Drug (ARNA) (OREX)
Tweet Send to a FriendGet Alerts VVUS Hot Sheet
Trade VVUS Now!
Amid Jefferies downgrading VIVUS (Nasdaq: VVUS) earlier on risk of generic prescriptions, peers are feeling the pressure Friday morning.
Shares of VIVUS are down over 6 percent, while Arena Pharma (Nasdaq: ARNA) down about 1 percent and Orexigen (Nasdaq: OREX) is flat, for now.
Recently, VIVUS won FDA approval for its obesity pill Qsymia, while Arena's weight-loss drug BELVIQ was approved by the FDA in June. Orexigen has Contrave in the works, with testing for the effects of its drug on the heart ongoing.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Shares of VIVUS are down over 6 percent, while Arena Pharma (Nasdaq: ARNA) down about 1 percent and Orexigen (Nasdaq: OREX) is flat, for now.
Recently, VIVUS won FDA approval for its obesity pill Qsymia, while Arena's weight-loss drug BELVIQ was approved by the FDA in June. Orexigen has Contrave in the works, with testing for the effects of its drug on the heart ongoing.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Yahoo! (YHOO) Board Said to Approve $1.1B Tumblr Deal
- Apple (AAPL) Continues Higher
- Friday's Hot IPOs Get Even Hotter (MKTO) (DATA)
Create E-mail Alert Related Categories
Momentum Movers, Trader TalkRelated Entities
Jefferies & Co
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
